Hormone Replacement Therapy Trial for Alzheimer's Disease Postmenopausal Women Evaluating Blood Markers of Amyloid Metabolism

What this Trial Is About

Researchers are investigating how hormone treatment after menopause might influence dementia, specifically Alzheimer's disease. The study focuses on the metabolism of amyloid, a substance involved in Alzheimer's, by measuring its degradation products in the blood. This work aims to better understand the relationship between menopause, hormone therapy, and Alzheimer's risk in postmenopausal women, including those with and without a history of breast cancer. Participants will have blood samples taken to analyze the breakdown products of amyloid metabolism. These blood tests are the main procedure in this trial, and the samples will be analyzed two years after the first participant is included to assess specific markers like APOE genotyping and BACE1 levels. The study includes postmenopausal women aged 40 to 65. During the study, participants will provide blood samples that will be evaluated for amyloid degradation products and genetic markers. The primary outcomes focus on changes in these blood markers over two years. The trial involves monitoring participants' health and collecting data that may offer insights into menopausal hormone therapy's effects on Alzheimer's disease progression or risk.

Hormone Replacement Trial Against ALzheimers' Disease